Moreover, the antibody drug conjugate (ADC) Sacituzumab Govitecan-hziy, which contains a humanized anti-Trop-2 monoclonal antibody and the topoisomerase I inhibitor drug SN-38 [21,22], was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) [23] based on the results of the randomized phase III ASCENT study. This evidence concerns the gene TACSTD2 and triple-negative breast carcinoma.